Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Gland Pharma stock

GLAND.NS
INE068V01023

Price

1,770.00
Today +/-
-0.04
Today %
-0.23 %
P

Gland Pharma stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Gland Pharma stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Gland Pharma stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Gland Pharma stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Gland Pharma's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Gland Pharma Stock Price History

DateGland Pharma Price
11/18/20241,770.00 undefined
11/14/20241,774.00 undefined
11/13/20241,703.40 undefined
11/12/20241,764.55 undefined
11/11/20241,818.10 undefined
11/8/20241,777.60 undefined
11/7/20241,803.80 undefined
11/6/20241,856.35 undefined
11/5/20241,832.85 undefined
11/4/20241,609.00 undefined
11/1/20241,642.75 undefined
10/31/20241,651.00 undefined
10/30/20241,642.15 undefined
10/29/20241,627.00 undefined
10/28/20241,624.55 undefined
10/25/20241,605.85 undefined
10/24/20241,641.95 undefined
10/23/20241,607.35 undefined
10/22/20241,647.60 undefined
10/21/20241,675.30 undefined

Gland Pharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Gland Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Gland Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Gland Pharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Gland Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Gland Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Gland Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Gland Pharma’s growth potential.

Gland Pharma Revenue, EBIT and net profit per share

DateGland Pharma RevenueGland Pharma EBITGland Pharma Net Income
2027e79.89 B undefined16.97 B undefined13.68 B undefined
2026e72.16 B undefined14.47 B undefined11.84 B undefined
2025e64.4 B undefined11.14 B undefined8.93 B undefined
202456.65 B undefined9.89 B undefined7.72 B undefined
202336.25 B undefined8.84 B undefined7.81 B undefined
202244.01 B undefined14 B undefined12.12 B undefined
202134.63 B undefined12.03 B undefined9.97 B undefined
202026.33 B undefined8.61 B undefined7.73 B undefined
201920.44 B undefined6.24 B undefined4.52 B undefined
201816.23 B undefined4.99 B undefined3.21 B undefined

Gland Pharma Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20182019202020212022202320242025e2026e2027e
16.2320.4426.3334.6344.0136.2556.6564.472.1679.89
-25.9628.8131.5127.09-17.6456.2813.6912.0410.72
57.8356.7956.8555.5851.1652.1860.6153.3147.5842.98
9.3911.6114.9719.2522.5118.9134.33000
3.214.527.739.9712.127.817.728.9311.8413.68
-40.7371.0328.9821.54-35.54-1.1015.6032.5815.58
163163163158.28164.54164.68164.73000
----------
Details

Keystats

ⓘ

Revenue and Growth

The Gland Pharma Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Gland Pharma is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (B)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (M)INTANGIBLE ASSETS (B)GOODWILL (B)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (B)PROVISIONS (M)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (B)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (B)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
2018201920202021202220232024
             
6.747.613.430.0632.4337.6319.39
4.755.066.027.1312.5610.2416.97
0.520.390.480.351.041.141.94
5.139.127.5612.8812.2919.7816.76
0.181.410.820.20.221.39
17.3223.5828.4651.2458.5269.0156.45
10.4310.5311.5712.9216.817.3638.3
0.060.060.070006.55
5843742144.99536.91854.83697.57
00000.130.121.12
0000002.42
1.430.630.340.762.350.431.07
11.9711.6612.413.7219.8218.7750.16
29.335.2440.8664.9678.3487.78106.61
             
155155155163.59164.3164.7164.71
5.895.895.8918.418.9519.2819.29
18.0722.5930.4940.5552.5460.2467.96
-15-17-69-77.94-82.52-96.9-175.55
0000000
24.128.6236.4659.0371.5879.5987.24
2.924.462.494.014.635.878.63
000000389.78
0.870.861.091.121.191.412.66
0000001.67
56102.972.617.09638.26
3.795.333.595.135.827.2913.98
0.070.060.050.050.040.041.41
0.961.080.740.740.880.842.2
0.380.150.020.020.020.021.78
1.41.290.810.80.940.95.39
5.196.624.45.936.768.1919.37
29.335.2440.8664.9678.3487.78106.61
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Gland Pharma provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Gland Pharma's financial health and stability.

Assets

Gland Pharma's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Gland Pharma must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Gland Pharma after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Gland Pharma's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201820192020202120222023
5.016.869.9313.3516.1910.55
0.780.820.950.991.11.47
000000
-3,505-5,774-3,240-7,471-7,995-7,288
-271-57-624-814-1,384-1,085
322662233462
1.572.232.443.114.073.11
2.021.857.016.057.913.64
-851-1,357-1,946-2,287-5,221-2,231
-3.59-3.14-7.66-15.24-10.0312.08
-2.74-1.78-5.71-12.95-4.8114.31
000000
-5-5-6-10-2-2
00012.420.390.21
-0.04-0.03-0.0712.380.350.15
-32.00-26.00-62.00-23.00-34.00-62.00
000000
-1.6-1.36-0.673.23-1.7415.9
1,169.3495.25,062.83,761.532,686.51,408.49
000000

Gland Pharma stock margins

The Gland Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Gland Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Gland Pharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Gland Pharma's sales revenue. A higher gross margin percentage indicates that the Gland Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Gland Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Gland Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Gland Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Gland Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Gland Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Gland Pharma Margin History

Gland Pharma Gross marginGland Pharma Profit marginGland Pharma EBIT marginGland Pharma Profit margin
2027e60.61 %21.24 %17.13 %
2026e60.61 %20.05 %16.41 %
2025e60.61 %17.29 %13.87 %
202460.61 %17.45 %13.64 %
202352.18 %24.4 %21.55 %
202251.16 %31.81 %27.53 %
202155.58 %34.75 %28.79 %
202056.85 %32.69 %29.35 %
201956.79 %30.54 %22.11 %
201857.83 %30.77 %19.79 %

Gland Pharma Stock Sales Revenue, EBIT, Earnings per Share

The Gland Pharma earnings per share therefore indicates how much revenue Gland Pharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Gland Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Gland Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Gland Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Gland Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Gland Pharma Revenue, EBIT and net profit per share

DateGland Pharma Sales per ShareGland Pharma EBIT per shareGland Pharma Earnings per Share
2027e484.92 undefined0 undefined83.05 undefined
2026e437.97 undefined0 undefined71.86 undefined
2025e390.91 undefined0 undefined54.2 undefined
2024343.87 undefined60.01 undefined46.89 undefined
2023220.1 undefined53.71 undefined47.43 undefined
2022267.46 undefined85.09 undefined73.64 undefined
2021218.78 undefined76.03 undefined62.99 undefined
2020161.55 undefined52.82 undefined47.42 undefined
2019125.41 undefined38.31 undefined27.72 undefined
201899.56 undefined30.64 undefined19.7 undefined

Gland Pharma business model

Gland Pharma is one of the most popular companies on Eulerpool.com.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Gland Pharma Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Gland Pharma historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Gland Pharma shares outstanding

The number of shares was Gland Pharma in 2023 — This indicates how many shares 164.68 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Gland Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Gland Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Gland Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Gland Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Gland Pharma dividend history and estimates

In 2023, Gland Pharma paid a dividend amounting to 0 INR. Dividend means that Gland Pharma distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Gland Pharma provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Gland Pharma’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Gland Pharma's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Gland Pharma Dividend History

DateGland Pharma Dividend
202420 undefined
Gland Pharma does not pay out any dividends.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Gland Pharma.

Gland Pharma latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/202414.41 8.73  (-39.44 %)2025 Q1
3/31/202413.72 11.68  (-14.85 %)2024 Q4
12/31/202314.43 11.65  (-19.25 %)2024 Q3
9/30/202312.28 11.78  (-4.05 %)2024 Q2
6/30/20239.68 11.78  (21.73 %)2024 Q1
3/31/202314.27 8.2  (-42.55 %)2023 Q4
12/31/202217.45 14.08  (-19.3 %)2023 Q3
9/30/202216.74 14.65  (-12.47 %)2023 Q2
6/30/202218.85 13.92  (-26.15 %)2023 Q1
3/31/202217.61 17.36  (-1.44 %)2022 Q4
1
2

Eulerpool ESG Scorecard© for the Gland Pharma stock

Eulerpool World ESG Rating (EESG©)

58/ 100

🌱 Environment

53

👫 Social

65

🏛️ Governance

56

Environment

Scope 1 - Direct Emissions
11,929.6
Scope 2 - Indirect emissions from purchased energy
80,669.6
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
92,599.2
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees13
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Gland Pharma shareholders

%
Name
Stocks
Change
Date
51.83180 % Shanghai Fosun Pharmaceutical Group Co Ltd85,393,934-9,900,0006/30/2024
7.01958 % Mirae Asset Global Investments (India) Pvt. Ltd.11,564,8951,010,8966/24/2024
6.39733 % HDFC Asset Management Co., Ltd.10,539,72260,5909/30/2024
6.34331 % Nippon Life India Asset Management Limited10,450,724-11,1119/30/2024
4.76149 % ICICI Prudential Asset Management Co. Ltd.7,844,655759,5609/30/2024
3.30207 % SBI Funds Management Pvt. Ltd.5,440,219-451,5976/30/2024
1.70400 % Aditya Birla Sun Life AMC Limited2,807,3821,400,1766/30/2024
1.48040 % UTI Asset Management Co. Ltd.2,438,9882,7249/30/2024
1.24033 % Goldman Sachs Asset Management International2,043,47476,9687/31/2024
0.86278 % Norges Bank Investment Management (NBIM)1,421,446339,1066/30/2024
1
2
3
4
5
...
10

Gland Pharma Executives and Management Board

Mr. Srinivasa Sadu(54)
Gland Pharma Chief Executive Officer, Managing Director, Whole-Time Director (since 2011)
Compensation 70.67 M
Mr. Ravi Mitra(46)
Gland Pharma Chief Financial Officer
Compensation 19.47 M
Ms. Naina Kidwai(66)
Gland Pharma Non-Executive Independent Director
Compensation 10.8 M
Mr. Yiu Kwan Lau(68)
Gland Pharma Non-Executive Independent Chairman of the Board
Compensation 5.74 M
Mr. P. Sampath Kumar(42)
Gland Pharma Compliance Officer, Company Secretary (since 2020)
Compensation 5.08 M
1
2
3

Most common questions regarding Gland Pharma

What is the P/E ratio of Gland Pharma 2024?

The Gland Pharma P/E ratio is 37.75.

What is the P/S ratio of Gland Pharma 2024?

The Gland Pharma P/S ratio is 5.15.

What is the Quality Investing of Gland Pharma?

The Quality Investing for Gland Pharma is 3/10.

What is the revenue of Gland Pharma 2024?

The Gland Pharma revenue is 56.65 B INR.

How high is the profit of Gland Pharma 2024?

The Gland Pharma profit is 7.72 B INR.

What is the business model of Gland Pharma

No history available for Gland Pharma.

What is the Gland Pharma dividend?

Gland Pharma pays a dividend of 0 INR distributed over payouts per year.

How often does Gland Pharma pay dividends?

The dividend cannot currently be calculated for Gland Pharma or the company does not pay out a dividend.

What is the Gland Pharma ISIN?

The ISIN of Gland Pharma is INE068V01023.

What is the Gland Pharma ticker?

The ticker of Gland Pharma is GLAND.NS.

How much dividend does Gland Pharma pay?

Over the past 12 months, Gland Pharma paid a dividend of 20 INR . This corresponds to a dividend yield of about 1.13 %. For the coming 12 months, Gland Pharma is expected to pay a dividend of 20 INR.

What is the dividend yield of Gland Pharma?

The current dividend yield of Gland Pharma is 1.13 %.

When does Gland Pharma pay dividends?

Gland Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Gland Pharma?

Gland Pharma paid dividends every year for the past 0 years.

What is the dividend of Gland Pharma?

For the upcoming 12 months, dividends amounting to 20 INR are expected. This corresponds to a dividend yield of 1.13 %.

In which sector is Gland Pharma located?

Gland Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Gland Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Gland Pharma from 9/29/2024 amounting to 20 INR, you needed to have the stock in your portfolio before the ex-date on 8/16/2024.

When did Gland Pharma pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Gland Pharma in the year 2023?

In the year 2023, Gland Pharma distributed 0 INR as dividends.

In which currency does Gland Pharma pay out the dividend?

The dividends of Gland Pharma are distributed in INR.

All fundamentals about Gland Pharma

Our stock analysis for Gland Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Gland Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.